SCHEMBL8058537

SCHEMBL8058537

CCOC(=O)c1cc(/C=C/c2ccc(S(=O)(=O)Nc3ncccc3C)cc2)c(F)cc1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A11 Q9UPY5 2/20 0.47
MCL1 Q07820 1/20 0.41
THRB P10828 1/20 0.40
MAPT P10636 4/20 0.40
HTT P42858 4/20 0.40
ALDH1A1 P00352 3/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP2C19 P33261 1/20 0.40
LMNA P02545 5/20 0.39
NPC1 O15118 2/20 0.39
KDM4E B2RXH2 1/20 0.39
GAA P10253 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
HPGD P15428 3/20 0.38
KMT2A Q03164 3/20 0.38
TSHR P16473 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8058540 1.00 SLC7A11 (0.47) SLC7A11MCL1THRBMAPTHTT
SCHEMBL4914202 0.89 SLC7A11 (0.59) SLC7A11MAPTALDH1A1MAPK1LMNA
SCHEMBL4914197 0.89 SLC7A11 (0.59) SLC7A11MAPTALDH1A1MAPK1LMNA
SCHEMBL27333277 0.85 CYP3A4 (0.36) SLC7A11MCL1THRBMAPTHTT
SCHEMBL8072327 0.81 SLC7A11 (0.60) SLC7A11THRBMAPTHTTALDH1A1
SCHEMBL8068575 0.79 SLC7A11 (0.52) SLC7A11MCL1THRBMAPTHTT
SCHEMBL8068573 0.79 SLC7A11 (0.52) SLC7A11MCL1THRBMAPTHTT
SCHEMBL9144880 0.79 SLC7A11 (0.58) SLC7A11MAPTNPC1KDM4EGAA
SCHEMBL9144877 0.79 SLC7A11 (0.58) SLC7A11MAPTNPC1KDM4EGAA
SCHEMBL8067186 0.77 SLC7A11 (0.77) SLC7A11THRBMAPTHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0613468-B1 Substituted salicylic acids for the treatment of autoimmune diseases PHARMACIA & UPJOHN AB (SE) 2000-07-12 EP disclosed
US-5556855-A TREATMENT OF AUTOIMMUNE DISEASES PHARMACIA AB (SE) 1996-09-17 US disclosed
US-5403930-A Chemical intermediate for drugs used in autoimmune diseases PHARMACIA AB (SE) 1995-04-04 US disclosed
EP-0613468-A1 NOVEL SUBSTITUTED SALICYCLIC ACIDS Pharmacia & Upjohn Aktiebolag (SE) 1994-09-07 EP disclosed
US-5302718-A Used for treating autoimmune diseases KABI PHARMACIA AB (SE) 1994-04-12 US disclosed
WO-1993010094-A1 NOVEL SUBSTITUTED SALICYCLIC ACIDS KABI PHARMACIA AB (SE) 1993-05-27 WO disclosed